• Should One Failed Test Be Enough to Shut Down a Drug Factory?
    Nov 18 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we look at a draft rule from India’s Health Ministry that would suspend a drug factory’s licence the moment its medicine fails one of five key quality tests. Today, a failed lab report leads to a notice, a reply and a wait, and the medicine can stay on shelves in the meantime. We explain what the draft says, why the ministry wants to change this, and why some may worry about acting on a single lab result. We also look at why the solvents used in syrups are getting a paperwork trail of their own.

    We’ll cover:

    • How the current process works after a medicine fails a test.
    • What the draft rule would change.
    • Why supporters and critics see it differently.
    • What it could mean for patients, and what we still don’t know.
    • Why solvents used in syrups are getting extra checks.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    6 mins
  • Can India’s First Homegrown Antibiotic Help Beat Superbugs?
    Nov 18 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we look at an antibiotic that, according to its maker Wockhardt, is the first new medicine fully discovered and developed by an Indian company to be approved by the US FDA. It is designed for serious infections caused by bacteria that resist many existing antibiotics, a growing problem known as antimicrobial resistance. We explain how the medicine works, what its trial showed, and why one new antibiotic does not solve the bigger problem. We also look at who pays for the next generation of antibiotics, as World AMR Awareness Week continues.

    We’ll cover:

    • Why antibiotics are losing their power against some infections.
    • How the new medicine fights bacteria in two ways at once.
    • What the trial showed, and what it has not yet shown.
    • What it could mean for patients, and what we still don’t know, including price and Indian launch.
    • Why new antibiotics are hard to fund.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    6 mins
  • Can the World Stop an Ebola Outbreak That Has No Vaccine?
    Nov 17 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we look at an Ebola outbreak in the Democratic Republic of the Congo caused by a strain that has no approved vaccine or treatment made for it. The World Health Organization has just recommended adding two new vaccine candidates to a trial in the country, including one developed by Oxford with the Serum Institute of India. We explain how a vaccine trial works in the middle of an outbreak, why this strain is harder to fight, and what is still unknown. We also look at how cheaper malaria vaccines made in India could reach more children.

    We’ll cover:

    • Why this Ebola strain is different from the one the current vaccine targets.
    • How vaccines are tested during an outbreak.
    • What the new trials could mean for patients, and what we still don’t know.
    • Why WHO says vaccines alone will not end the outbreak.
    • How cheaper malaria vaccines could reach more children.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    7 mins
  • Can a Cancer Vaccine Made for One Person Change Treatment?
    Nov 16 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we look at a cancer vaccine that is made from each patient’s own tumour and has just passed its biggest test so far. We explain how a vaccine can treat a cancer that is already there, what the trial showed, and why the result has been read in two very different ways. We also look at a new US approach that could make it easier to create gene-editing treatments for one patient at a time, and why that matters for who gets access to such medicines.

    We’ll cover:

    • How a vaccine is built from a patient’s own tumour.
    • What the late-stage trial showed, and what is still missing.
    • Why supporters and sceptics read the result differently.
    • What it could mean for patients, and what we still don’t know, including price and approval.
    • How a proposed US pathway could speed up treatments designed for a single patient.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    7 mins
  • Can China Stop Its Biotech Secrets From Leaving the Country?
    Nov 15 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, we look at a draft rule from China that could stop its companies from selling the core toolkits behind some of the newest medicines to foreign buyers. These toolkits, called platforms, can turn out many drugs and not just one, which is why they matter so much. We explain what the draft says, what it still allows, and why law firms are already busy. We also look at a parallel move in Washington, and what the squeeze from both sides could mean for companies in India.

    We’ll cover:

    • What China’s draft rule would ban, and what it would still allow.
    • Why a “platform” is like a whole kitchen and not a single dish.
    • Why deals already under way are being affected.
    • How the US is drawing its own lines around biotech.
    • What it could mean for patients and Indian companies, and what we still don’t know.
    • Also on the radar: the US measles decision and World AMR Awareness Week.
    Show More Show Less
    7 mins
  • Is the US About to Lose a Public Health Title It Has Held for 25 Years?
    Nov 14 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    In this episode of Pharma Explained, by Pharma Now, we ask whether the United States is about to lose a public health title it has held for 25 years. An expert commission of the Pan American Health Organization has just reviewed whether the country still counts as having eliminated measles, and its recommendation is now with the organization’s director. We explain what “eliminated” really means, why it does not mean zero cases, and how experts use the virus’s genetic sequences to decide. We also look at where India stands on its own measles and rubella elimination target, which falls this year.

    We’ll cover:

    • What it means for a country to eliminate measles.
    • How a virus’s genetic family tree decides whether a country keeps its status.
    • Why health officials and critics read the label differently.
    • What it could mean for patients and families, and what we still don’t know.
    • Where India stands on its own measles and rubella target.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    6 mins
  • What Happened After Semaglutide Went Generic in India
    Nov 14 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    Semaglutide, the ingredient behind weekly injections for diabetes and weight management, lost its main patent in India this year, and a dozen or so companies launched their own versions almost overnight. The seventh episode of Pharma Explained looks at what has changed for prices, brands and patients, and how the same patent expiry is playing out in other countries.

    We’ll cover:

    • How the generic launch has changed what patients can buy and what it costs.
    • How the original makers have responded.
    • What it could mean for patient safety, daily life and your wallet.
    • How Brazil, Canada and China compare with India.
    • What we still don’t know, including how many patients will stay on treatment.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    6 mins
  • Who Pays When a Doctor Takes a Free Trip, and Should the Company Face the Same Consequence?
    Nov 14 2026

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode!

    Doctors in India are not allowed to accept gifts or sponsored foreign trips from pharma companies. But if the rules are broken, the doctor can lose a licence, while the company faces an industry-run process. In this episode of Pharma Explained, we look at who pays the price, and whether the law should reach companies too.

    We’ll cover:

    • What India’s pharma marketing code allows and bans.
    • Why doctors and companies face different consequences.
    • How the US approach to disclosure compares with India’s.
    • What it could mean for patients, and what we still don’t know.

    For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.

    Follow Pharma Now’s social handles:

    • LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/pharma-now/?viewAsMember=true⁠⁠⁠
    • Facebook: ⁠⁠⁠https://www.facebook.com/profile.php?id=61559659700692⁠⁠⁠
    • X: ⁠⁠⁠https://x.com/PharmaNowGlobal⁠⁠⁠
    • Instagram: ⁠⁠⁠https://www.instagram.com/pharmanow.live/⁠⁠⁠

    Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.

    Show More Show Less
    7 mins